| |
Genedata, a leader in providing in silico solutions for the worldwide life sciences industry, today announced an agreement with the Fiehn Laboratory at the University of California, Davis, for the provision of the Expressionist software platform for biomarker discovery. Both Refiner MS and Analyst modules will be used for mass spectrometry-based metabolomics analyses to classify patient samples and identify biomarkers.
Genedata’s Refiner MS software module performs high-throughput processing and automated quality analysis of mass spectrometry-based proteomics and metabolomics data. Refiner MS enables researchers to process hundreds of gigabytes of data simultaneously, while Analyst provides a comprehensive statistical analysis platform that allows these processed data to be compared with microarrays, bead-based assays, qPCR, 2D-PAGE, 2D-DIGE and NMR data, as well as additional types of MS data. This integrated view helps researchers to understand the action of all biomolecules in a single, comprehensive system.
Dr. Oliver Fiehn, Associate Professor at the UC Davis Genome Center, explained, “Given our extensive work with infusion MS and LC-MS, Genedata’s ability to work concurrently with both the raw data and extracted peaks will greatly facilitate our research. There are other systems available to handle portions of our workflow, but Genedata is unique in their capability to handle the breadth of our research processes. Their ability to handle hundreds of samples and hundreds of gigabytes of data simultaneously combined with the support for all of the MS hardware providers and MS setups made Genedata the obvious choice for us. We feel that the combination of the Refiner MS and Analyst modules is a powerful enhancer to our biomarker detection efforts, and will enable our researchers to identify biomarkers that could be missed using other methods and tools.”
Dr. Jens Hoefkens, Managing Director of Genedata Inc., said, “We are delighted that Genedata software has been selected by researchers at UC Davis. We consider this agreement as further validation that our in silico offerings provide compelling advantages to scientists in prominent life sciences research institutions. We look forward to working with the Genome Center in their efforts to find novel approaches for identifying metabolites.”
Genedata specializes in discovery informatics for biotech, pharmaceuticals and the life sciences. The Company offers expertise in research informatics combined with open and scalable computational solutions. Our solutions include Genedata Phylosopher® for integrating, structuring, and analyzing research data. Genedata Screener® for high throughput screening analysis. And Genedata Expressionist® for omics data integration, processing and analysis. Founded in 1997 as a privately held spin off from Novartis, Genedata is headquartered in Basel, Switzerland and has branches in Tokyo (Japan), Munich (Germany), Boston (USA) and San Francisco (USA). The Company is also represented in Taiwan and Singapore.
Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
|
Kurt.Zingler[.]genedata.com 
